Date published: 10-04-2012
Chalfont St Giles, UK, and Pine Brook, NJ – 10 April 2012 – GE Healthcare, the healthcare business of GE (NYSE: GE) has signed a worldwide supply and distribution agreement with Refine Technology, a manufacturer and supplier of novel filtration systems for use in biopharmaceutical manufacturing. Under the terms of the agreement, GE Healthcare will supply Refine Technology with its innovative hollow fiber filtration cartridges for use with Refine Technology’s ATF™ system.
Refine Technology’s ATF System is a cell retention device used in manufacture of biopharmaceuticals to generate extremely high concentrations of cells ready for further processing. Continuous processing offers a number of significant advantages over traditional batch manufacturing methods, such as more rapid isolation of cells, shorter manufacturing times and improved safety profiles. GE Healthcare’s ultrafiltration and microfiltration hollow fiber cartridges, which are used with the ATF System, are ISO 9001:2000 certified, autoclave-able for sterile repeat use, and available in a wide range of formats and specifications to help customers optimize their manufacturing process for maximum productivity.
Catarina Flyborg, BioProcess Product Marketing Leader, GE Healthcare Life Sciences, said, “GE Healthcare and Refine Technology have established a platform for future collaboration, a crucial step in helping both companies meet the new and emerging demands of the rapidly-changing biomanufacturing market. The relationship also helps support the FDA’s goal1 of achieving continuous processing across the industry.”
“We are excited to be working in collaboration with GE Healthcare and to be able to supply our customers with a broad range of GE Healthcare’s high quality hollow fiber filters that offer them enhanced flexibility in their processes,” commented Jerry Shevitz, President of Refine Technology, “and it is satisfying to see that our relationship will be deepened and extended by this new agreement.”
1. Continuous Manufacturing – FDA Perspective on Submissions and Implementation, PQRI Workshop, September 11th, 2011
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems. Our “healthy magination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.
About Refine Technology
Refine Technology develops and commercializes equipment for the enhancement of cell culture processes. Its ATF System, which scales for use in the laboratory through to commercial manufacturing, has a range of uses from simple culture maintenance, to generation of ‘extreme’ cultures, to complex vaccine manufacturing. Refine Technology is dedicated to quality, customer support and providing solutions to a rapidly evolving biopharmaceutical industry. Based in New Jersey, USA, Refine Technology distributes and services products worldwide through its network of highly trained sales and support personnel. For more information about Refine Technology, visit our website at www.refinetech.com.
Dr Val Jones, Global Media Relations Manager
T +44 7917 175 192
John Bonham-Carter, VP Business Development
T +1 732 993 3003
T +46 76 256 5114